Passage Bio : Announces Pennsylvania Scholars Program to Honor Legacy of Biopharma Pioneer Dr. Tachi Yamada

Published: 2021-10-06 08:46:09 ET PASG

Philadelphia, PA - October 6, 2021 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, announced a scholarship program dedicated to fostering education and innovation in the life sciences in honor of Passage Bio co-founder and Board Chairman in Memoriam Tadataka (Tachi) Yamada, M.D. Dr. Yamada, who passed away in August 2021, had a life-longdevotion to building the next generation of scientists. The new scholars program will continue his legacy by granting a scholarship to a rising junior enrolled in a life sciences program at a Pennsylvania four-year college or university.

"Tachi was a brilliant researcher and visionary leader who was committed to mentoring people who shared his passion for improving healthcare," said Bruce Goldsmith, Ph.D., president and CEO, Passage Bio. "With this scholarship program, we are proud to honor Tachi's legacy by nurturing budding scientists who will help to drive continued innovation in the Pennsylvania life sciences community."

In addition to the financial award, the select scholar will be matched with a Passage Bio mentor for professional growth opportunities. Detailed information on the program and application process will be available in January 2022.

The Tachi Yamada Scholar program adds to Passage Bio's commitment to advancing the Pennsylvania life sciences community through support for organizations like LifeSciencesPA and Life Science Cares Philadelphia. The company announced the award at Life Sciences Pennsylvania's annual conference, Life Sciences Future - BioPharm.

About Passage Bio

At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming genetic medicines for patients with CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania's Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

Investors: Stuart Henderson Passage Bio 267.866.0114 [email protected]

Media: Gwen Fisher Passage Bio 215.407.1548 [email protected]

Multimedia Files:

Disclaimer

Passage Bio Inc. published this content on 06 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 October 2021 12:45:04 UTC.